| Category: Anticancer
Each vial contains:-
Epirubicin - 10mg , 50mg and 100mg
Quality Specification:
Chromatographic Purity: NLT 99.5%
It is a new anthracycline antibiotic with antiblastic activity. The mechanism of action of it is related to its ability to bind to DNA. Cell culture studies have shown rapid cell penetration, localization in the nucleus and inhibition of nucleic acid synthesis and mitosis.
| Composition : | 10mg/50mg, 100mg | | Indication : | Breast carcinoma; malignant lymphomas; soft tissue sarcoma; Gastric, hepatic, pancreatic and sigma-rectum carcinomas; head and neck carcinoma; And leukemias. | | Dosage :- | 60-90 mg/ml body area; the drug should be injected through i.v. over 3-5 minutes and depending on the patient’s haematomedullar status, the dose should be repeated at 21-day intervals. Lower doses(60-75 mg/ml) are recommended for patient’s whose bone marrow function has already been impaired by previous chemotherapy or radio therapy, by age or neoplastic bone- marrow infiltration. The total dose per cycle may be divided over 2-3 successive days. When the drug is used in combination with other antitumour agents, the doses needs to be adequately reduced. | | Contra Indications:- | In patients with marked myelosuppression induced by previous treatments with other antitumour agents or by radio-therapy. Previous history of cardiac impairment. Hypersensitivity. | | Special Precautions:- | White and red blood cells and platelet counts should be carefully monitored. Cardiac function must be carefully monitored. Pregnancy. | | Side Effects:- | Alopecia, mucositis, stomatitis with areas of painful erosions, gastro- intestinal disturbances, such as nausea, vomiting and diarrhea, hyperpyrexia. | | Purity : | Not less than 99%. |
|
 |
© Health Biotech Limited. All Rights Reserved (Terms of Use)
